Paradigm Shift Intervention Monitoring
twitter
Commentary
FDA Announces Shortage of Children's Tamiflu
Recombinomics Commentary 21:00
January 7, 2014
Genentech is experiencing temporary delays in manufacturing of Oral suspension. A brief shortage of Oral Suspension is expected in early--‐mid January.
Please check with authorized Genentech distributors and retailers for product availability. Genentech expects to have additional supply of Tamiflu for Oral Suspension mid-January 2014.
The above comments are from the FDA website, citing a shortage of children’s (oral suspension) of oseltamivir (Tamiflu). The website gives detail, including product number and company access, as well as compounding remarks. The reason for the shortage is demand.
Similar shortages arose in 2009, when pH1N1 dramatically spread. The current shortage highlights the public’s concern driven in part by media coverage.
However, most of the reported deaths have been in middle age adults, where the level of H1N1 is beginning to rise, raising concerns that the death toll, as well as demand for children’s and adult oseltamivir will increase significantly.
Details on supplies and production of adult oseltamivir would be useful.
Recombinomics
Presentations
Recombinomics
Publications
Recombinomics
Paper
at Nature Precedings